A groundbreaking study presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego has sparked hope for cancer patients. The Williams Cancer Institute, a pioneer in intratumoral immunotherapy, unveiled data from its research on combining pulsed electrical field ablation and intratumoral immunotherapy for head and neck squamous cell carcinoma (HNSCC).
Dr. Jason Williams, the institute's founder and director, emphasized the potential of this combination approach. "Our findings suggest a promising future for treating HNSCC, a complex and often aggressive cancer. By activating an immune response, we can offer new treatment options for patients who have exhausted conventional therapies."
HNSCC, commonly caused by tobacco or HPV, is notoriously difficult to treat due to its late-stage diagnosis and complex nature. The study focused on a patient with advanced HNSCC, who underwent a unique treatment regimen. This involved four cycles of pulsed electrical field ablation, a minimally invasive procedure, to disrupt tumor cells. Intratumoral immunotherapy injections, combined with imaging agents and local retention techniques, were then administered directly into the tumor.
The results were remarkable. The patient experienced substantial tumor regression and a long-lasting clinical response, with no treatment-related toxicity or complications. At 14 months, imaging showed significant tumor elimination, and by 22 months, the patient's disfiguring mass had completely resolved.
This study, titled "702 Pulsed electrical field ablation plus intratumoral immunotherapy for head and neck squamous cell carcinoma," was authored by Erik Soule, Carlos A Vargas, Eduardo Cortes, Nathan Goodyear, and Jason R Williams. It is available in full in the Journal for ImmunoTherapy of Cancer.
The Williams Cancer Institute, founded by Dr. Jason R. Williams, is dedicated to advancing intratumoral immunotherapy and providing safer, less invasive cancer treatment options for late-stage patients. Their work is a beacon of hope for those facing challenging cancers.
But here's where it gets controversial: Should this combination approach replace conventional therapies? Or is it best as a complementary treatment? What are your thoughts on the potential of intratumoral immunotherapy? Share your insights and let's spark a discussion!
